IMMUNITYBIO INC (IBRX)

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 725 full-time employees. The company went IPO on 2015-07-28. The firm is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its segment is focused on creating the next generation of immunotherapies to address serious unmet needs within oncology and infectious diseases. Its platforms include antibody cytokine fusion proteins; DNA, RNA, and recombinant protein vaccine technologies, including self-amplifying RNA, second-generation adenovirus hAd5 vector and recombinant protein platforms; toll-like receptor activating adjuvants; natural killer (NK) cell therapy, including off-the-shelf NK cells, and autologous and allogenic memory-like cytokine-enhanced NK cells (M-ceNK); damage-associated molecular patterns inducers, including Aldoxorubicin and Nanatinostat. Its clinical pipeline consists of over 26 clinical trials of which 17 are in Phase I or III development, across 13 indications in liquid and solid tumors.

Company Info

IMMUNITYBIO INC

3530 John Hopkins Court

San Diego CALIFORNIA 92121

P: 18446965235

CEO: Richard Adcock

Employees: 725

Website: https://immunitybio.com/